Literature DB >> 2195177

Radithor and the era of mild radium therapy.

R M Macklis1.   

Abstract

Soon after the discovery of radium, a school of practitioners arose who were interested primarily in the physiological rather than the tumoricidal powers of this new radioactive element. This treatment philosophy was called "mild radium therapy" and involved the oral or parenteral administration of microgram quantities of radium and its daughter isotopes, often as cures for rheumatic diseases, hypertension, and metabolic disorders. Manufacturers of patent medicines responded to this market by producing a variety of over-the-counter radioactive preparations including pills, elixirs, and salves. One such nostrum was Radithor, a popular and expensive mixture of radium 226 and radium 228 in distilled water. Radithor was advertised as an effective treatment for over 150 "endocrinologic" diseases, especially lassitude and sexual impotence. Over 400,000 bottles, each containing over 2 muCi (74 kBq) of radium, were apparently marketed and sold worldwide between 1925 and 1930. The death of the Pittsburgh millionaire sportsman Eben M. Byers, who was an avid Radithor user, by radium poisoning in 1932 brought an end to this era and prompted the development of regulatory controls for all radiopharmaceuticals.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2195177

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Radiation hormesis - fact or fiction?

Authors:  R Piispanen
Journal:  Environ Geochem Health       Date:  1995-06       Impact factor: 4.609

2.  Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy.

Authors:  Guozi Yang; Qingyu Kong; Guanjun Wang; Haofan Jin; Lei Zhou; Dehai Yu; Chao Niu; Wei Han; Wei Li; Jiuwei Cui
Journal:  Cancer Biother Radiopharm       Date:  2014-12       Impact factor: 3.099

3.  Radiation hormesis: historical perspective and implications for low-dose cancer risk assessment.

Authors:  Alexander M Vaiserman
Journal:  Dose Response       Date:  2010-01-18       Impact factor: 2.658

Review 4.  Hormetic Response to Low-Dose Radiation: Focus on the Immune System and Its Clinical Implications.

Authors:  Jiuwei Cui; Guozi Yang; Zhenyu Pan; Yuguang Zhao; Xinyue Liang; Wei Li; Lu Cai
Journal:  Int J Mol Sci       Date:  2017-01-27       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.